These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29771694)

  • 1. Fostemsavir: a new CD4 attachment inhibitor.
    Cahn P; Fink V; Patterson P
    Curr Opin HIV AIDS; 2018 Jul; 13(4):341-345. PubMed ID: 29771694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.
    Hiryak K; Koren DE
    Ann Pharmacother; 2021 Jun; 55(6):792-797. PubMed ID: 32964736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
    Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
    J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition.
    Lai YT
    Viruses; 2021 May; 13(5):. PubMed ID: 34066522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.
    Soulié C; Lambert-Niclot S; Fofana DB; Fourati S; Ait-Arkoub Z; Sayon S; Simon A; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2013 Jun; 68(6):1243-5. PubMed ID: 23396856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
    Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
    Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
    J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
    Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.